经颈静脉肝内门体分流术联合胃冠状静脉栓塞术治疗肝硬化门静脉高压症上消化道出血中远期疗效评价

肝脏 ›› 2016, Vol. 21 ›› Issue (1): 17-20.

经颈静脉肝内门体分流术联合胃冠状静脉栓塞术治疗肝硬化门静脉高压症上消化道出血中远期疗效评价

邵庆华, 郑盛, 杨涓, 张帆, 杨晋辉, 唐映梅

650011 云南省第三人民医院肝病中心（邵庆华,郑盛,杨涓,张帆）; 昆明医科大学第二附属医院肝病中心（杨晋辉,唐映梅）

收稿日期:2015-07-16 发布日期:2020-06-01
通讯作者: 唐映梅,Email：tangying mei_med@163.com
作者简介:共同第一作者：郑盛
基金资助:
国家自然科学基金（81360072）; 云南省自然科学基金（2012 FD095）; 云南省教育厅科研基金重点项目（2014Z125,2015Z146）

The mid-long-term clinical efficacy of transjugular intrahepatic portosystemic shunt com bined with gastric coronary vein em bolization for portal hypertension complicated by upper gastrointestinal bleeding

SHAO Qing-hua¹, ZHENG Sheng¹, YANG Juan¹, ZHANG Fan¹, YANG Jin-hui², TANG Ying-mei²

1. Departmentof Liver Diseases,Yunnan Thethird People’s Hospital,Kunming 650011,China;
2. Department of Liver Diseases,The Second Affiliated Hospital of Kunming Medical University,Kunming 650000,China

Received:2015-07-16 Published:2020-06-01
Contact: TANGYing-mei,Email：tangyingmei_med@163.com

摘要/Abstract

摘要： 目的评价经颈静脉肝内门体分流术（TIPS）联合胃冠状静脉栓塞术（GCVE）治疗门静脉高压症上消化道出血的中远期疗效。方法回顾性分析昆明医科大学第二附属医院肝病中心2008年1月至2013年1月间99例因肝硬化门静脉高压症上消化道出血行TIPS手术治疗的患者。其中43例行单纯TIPS治疗（TIPS组）,56例行TIPS联合组织胶定位栓塞治疗（TIPS+GCVE组）。测量、计算术前、术后两组患者直接门静脉压力（PVP）、门静脉压力梯度（PPG）。TIPS组、TIPS+GCVE组术前与术后PVP、PPG比较应用t检验;随访期间TIPS组和TIPS+GCVE组患者未发生上消化道再出血率、生存率和支架通畅率分析应用Kaplan-Meier法,进一步组间比较应用Log-rank检验。结果 TIPS组、TIPS+GCVE组术前PVP分别为（35.2±3.1）和（35.3±3.6）MMHg（1 MMHg=0.133 kPa）,术后PVP分别为（21.9±2.8）和（22.7±3.1）MMHg;TIPS组、TIPS+GCVE组术前PPG分别为（25.8±3.2）和（25.5±2.3）MMHg,术后PPG分别为（11.6±1.7）和（12.8±1.5）MMHg。两组患者术后PVP、PPG均较术前下降,且差异均有统计学意义（TIPS组：t=15. 772、15.722,均P=0.000;TIPS+GCVE组：t=31.069、31.096,均P=0.000）;而术前、术后两组PVP差异均无统计学意义。术前两组PPG差异无统计学意义,而术后TIPS+GCVE组PPG高于TIPS组,且差异有统计学意义（t=-4.726,P=0.000）。术后随访1~54个月,平均（36.3±11.1）个月。TIPS组患者术后6、12、24、48个月累积未发生上消化道再出血率分别为90.7％、86.0％、76.7％和65.1％,而TIPS+GCVE组患者分别为98.2％、92.6％、89.3％和85.7％,两组比较差异有统计学意义（χ²=5.987,P=0.014）;TIPS组患者术后6、12、24和48个月累积支架通畅率分别为95.3％、88.4％、79.1％和72.1％,TIPS+GCVE组患者分别为92.9％、87.5％、82.1％和78.6％,两组比较差异无统计学意义（χ²=0.736,P=0.328）;TIPS组患者术后6、12、24和48月累积生存率分别为93.0％、88.4％、83.7％和72.1％;TIPS+GCVE组患者分别为94.6％、92.9％、87.5％和80.4％,两组比较差异无统计学意义（χ²=2.18,P=0.094）。结论 TIPS联合GCVE治疗门静脉高压症上消化道出血,疗效肯定,再出血率低,是一种安全、有效的治疗方法。

关键词: 经颈静脉肝内门体分流术, 栓塞, 治疗性, 上消化道出血, 高血压, 门静脉, 食管和胃静脉曲张

Abstract: Objective To evaluate the mid-long-term clinical efficacy of transjugular intrahepatic portosystemic shunt （TIPS）combined with gastric coronary vein em bolization（GCVE）for portal hypertension complicated with upper gastrointestinal bleeding. Methods Ninety-nine cirrhosis patients,w ho had received TIPSfor upper gastrointestinal hem orrhage due to portal hypertension fro MJanuary 2008 to January 2013 in the second affiliated hospital of Kun ming Medical University,were retrospectively analyzed. AMong these patients,43 received TIPS（TIPSgroup）and 56 received TIPSplus GCVE（TIPS+GCVEgroup）.Portal venous pressure（PVP）and portal pressure gradient（PPG）of both groups before and after treatment were compared by Ttest. Upper gastrointestinal rebleeding rate,survival rate and stent patencybook=18,ebook=22rate in both groups during a follow-up were analyzed by Kaplan-Meier method,which was further compared by log-rank test between the two groups. Results Preoperative PVPin TIPSgroup and TIPS+GCVEgroup were（35.2±3.1）,（35.3± 3.6）MMHg（1 MMHg=0.133 kPa）,w hile postoperative PVPwere（21.9±2.8）,（22.7±3.1）MMHg;preoperative PPGin two groups were（25.8±3.2）,（25.5±2.3）MMHg,w hile postoperative PPGwere（11.6±1.7）,（12.8±1.5）MMHG. Postoperative PVPand PPGwere lower than preoperative ones in both groups,which showed statistically significant differences（TIPSgroup：t=15.772、15.722,P=0.000;TIPS+GCVEgroup：t=31.069、31.096,P=0.000,respectively）. However,there was no significant difference in PVPbefore and after treatment between two groups. Between the two groups,preoperative PPGshowed no significant difference,while postoperative PPGin TIPS+GCVEgroup was statistically significantly higher than thatin TIPSgroup（t=-4.726,P=0.000）. A1l cases were followed up for 1 to 54 Months after operation with an average of（36.3±11.1）Months. The free of variceal rebleeding rates in 6 Months,12 Months,24 Months and 48 Months after operation were 90.7％,86.0％,76.7％and 65.1％in TIPSgroup,respectively,and 98.2％,92.6％,89.3％and 85.7％in TIPS+GCVEgroup,respectively,which revealed statistically significant differences（χ²=5.987,P=0.014）. Stent patency rates in 6 Months,12 Months,24 Months and 48 Months after operation were 95.3％、88.4％、79.1％and 72.1％in TIPSgroup,respectively,and 92.9％、87.5％、82.1％and 78.6％in TIPS+GCVEgroup,respectively,which indicated no significant difference（χ²=0.736,P=0.328）. Survival rates in 6 Months,12 Months,24 Months and 48 Months after operation were 93.0％、88.4％、83.7％and 72.1％in TIPSgroup,respectively,and 94.6％、92.9％、87.5％and 80.4％in TIPS+GCVEgroup,respectively,which pointed out no significant difference（χ²=2.18,P=0.094）. Conclusion The combined treatment of TIPSwith GCVEcould reduce rebleeding rate of esophageal and gastric varices,which is More effective than TIPSalone,with reliable security and satisfactory long-term efficacy.

Key words: Transjugular intrahepatic portosystemic shunt, Therapeutic em bolization, Upper gastrointestinal bleeding, Hypertension, portal, Esophageal and gastric varices

邵庆华, 郑盛, 杨涓, 张帆, 杨晋辉, 唐映梅. 经颈静脉肝内门体分流术联合胃冠状静脉栓塞术治疗肝硬化门静脉高压症上消化道出血中远期疗效评价[J]. 肝脏, 2016, 21(1): 17-20.

SHAO Qing-hua, ZHENG Sheng, YANG Juan, ZHANG Fan, YANG Jin-hui, TANG Ying-mei. The mid-long-term clinical efficacy of transjugular intrahepatic portosystemic shunt com bined with gastric coronary vein em bolization for portal hypertension complicated by upper gastrointestinal bleeding[J]. Chinese Hepatolgy, 2016, 21(1): 17-20.

参考文献

1 Loffroy R,Estivalet L,Cherblanc V,et al.Transjugular intrahepatic portosystemic shunt for the management of acute variceal hem orrhage. World JGastroenterol,2013,19:6131-6143.
2 王洪波,张安忠,杨崇美,等.经颈内静脉肝内门体分流术联合胃冠状静脉栓塞治疗食管胃底静脉曲张疗效分析.中华医学杂志,2012,92:411-413.
3 Garcia-Tsao G,Sanyal AJ,Grace ND,et al.Prevention and management of gastroesophageal varices and variceal hem orrhage in cirrhosis. AMJGastroenterol,2007,102:2086-2102.
4 Qi XS,Han GH,He CY,et al.Transjugular intrahepatic portosystemic shunt may be superior to conservative therapy for variceal rebleeding in cirrhotic patients with non-tu Moral portal vein thro Mbosis:Ahypothesis. Med Sci Monit,2012,18:37-41.
5 Xue H,Zhang M,Pang J,et al.Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding. World JGastroenterol,2012,18:7341-7347.
6 Garcia-Pagan JC,Di Pascoli M,Caca K,et al.Use of early-TIPSfor high-risk variceal bleeding:Results of a post-RCTsurveillance study.JHepatol,2013,58:45-50.
7 Tesdal IK,Filser T,Weiss C,et al.Transjugular intrahepatic portosystemic shunts: adjunctive em bolotherapy of gastroesophageal collateral vessels in the prevention of variceal rebleeding. Radiology,2005,236:360-367.
8 唐承薇,李肖.肝硬化门静脉高压治疗策略.中国实用内科杂志,2011,31:79-80.
9 Perarnau JM,Le Gouge A,Nicolas C,et al.Covered vs uncovered stents for transjugular intrahepatic portosystemic shunt:a rando mized controlled trial.JHepatol,2014,60:962-968.
10 Chen S,Li X,Wei B,et al.Recurrent variceal bleeding and shunt patency:prospective rando mized controlled trial of transjugular intrahepatic portosystemic shunt alone or combined with coronary vein em bolization. Radiology,2013,268:900-906.
11 刘仕睿,丁鹏绪,化召辉,等.经颈静脉肝内静脉分流术联合胃冠状静脉栓塞治疗门静脉高压症上消化道出血.中华普通外科杂志,2015,30:101-103.
12 Do minique T,Kiyoka K,Nicolas W. Diagnosis of minimal hepatic encephalopathy in patients with cirrhosis:should we bury psycho metric tests. Hepatology,2014,59:2428-2430.

[1]	王家欢, 李震. ¹²⁵I放射粒子植入联合肝动脉栓塞术对原发性肝癌的疗效及对肝脏TRF1和TRF2表达影响[J]. 肝脏, 2020, 25(4): 402-406.
[2]	穆双锋, 李敬霞, 穆立祥. 三维适形放疗联合TACE治疗大肝癌患者肿瘤标志物水平及3年生存观察[J]. 肝脏, 2020, 25(4): 406-408.
[3]	周西, 刘启榆, 杨伟, 王忠, 范丹丹, 温凌字. CT能谱成像与MRI在肝细胞癌TACE术后疗效评估中的对比研究[J]. 肝脏, 2020, 25(4): 409-412.
[4]	吴斌, 宋琪琪, 何文涛, 吴东刚. 头孢哌酮舒巴坦对肝硬化合并上消化道出血患者院内感染效果的分析[J]. 肝脏, 2020, 25(4): 436-437.
[5]	杨怀龙, 雷霆. CT全灌注成像在肝癌TACE介入术前肝储备功能评估中的价值[J]. 肝脏, 2020, 25(3): 270-272.
[6]	余守江, 王国兴, 马兰芳. TACE联合微波消融对原发性肝癌患者肿瘤组织灌注、免疫功能及预后的影响[J]. 肝脏, 2020, 25(3): 294-296.
[7]	赵开飞, 谭瑞, 蒋国军, 石荣书, 韦鑫佩, 杜松丽. 脾动脉支架限流术治疗肝硬化门静脉高压的实验研究[J]. 肝脏, 2019, 24(9): 1019-1021.
[8]	王乃金, 应浩杰, 史进, 周文广, 苏珂. 血管瘤剥除术与肝动脉介入栓塞术治疗肝血管瘤疗效分析[J]. 肝脏, 2019, 24(9): 1040-1043.
[9]	卞志方. 微波消融术联合肝动脉栓塞治疗肝癌后早期复发的危险因素[J]. 肝脏, 2019, 24(9): 1065-1068.
[10]	魏玮, 相芳. 卡维地洛对肝硬化伴顽固性腹水患者门静脉血流动力学和存活质量的影响[J]. 肝脏, 2019, 24(8): 883-886.
[11]	杨帆, 程黎娜, 张玲娟, 李修岭. TIPS用于肝硬化门脉高压对患者远期预后的影响[J]. 肝脏, 2019, 24(8): 893-895.
[12]	黄潭玉, 周顺厚, 关天明. 肝癌致门静脉癌栓80例表观扩散系数及扩散加权成像表现分析[J]. 肝脏, 2019, 24(8): 896-898.
[13]	舒丹, 黄湘荣, 蒋育进, 黄婷, 刘映霞, 许诚. 肝硬化门静脉血栓形成高危因素的Logistic回归分析[J]. 肝脏, 2019, 24(7): 740-743.
[14]	李英, 高磊, 胡扬喜, 胡德升. 低分子肝素钙联合右旋糖酐在肝硬化门静脉高压症术后静脉血栓形成预防中的应用[J]. 肝脏, 2019, 24(7): 788-790.
[15]	熊静平, 范晓棠, 张跃新. 肝硬化并门静脉血栓脂代谢相关差异蛋白的研究[J]. 肝脏, 2019, 24(6): 645-648.